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Highlights  
 Outcome measures in substance misuse treatment tend to be multidimensional  
 There is similarity in the contents covered by outcome measures in this field  
 Outcome measures address contents reported by patients as relevant  
 There are topics of relevance for patients that outcome measures overlook  
 Outcome measures need to be complemented with individualised measures  
 
 
Abstract  
There are a growing number of authors stating that outcome measurement in treatment for 
substance use disorders should go beyond substance use and include other bio-psycho-social 
variables of interest. However, little is known about which topics tend to be covered by 
outcome measures and whether they reflect the typical concerns of this patient group. This 
study followed a scoping review methodology in which 42 outcome measures recommended 
by an EU agency for substance use disorders were reviewed. We identified the domains of 
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problems covered by these 42 measures and then compared them with 54 domains derived 
from patients, in a previous study. We also explored how similar the existing measures were 
in terms of domains covered, and which patient derived domains tended to be represented in 
those measures. We identified 31domains of problems across the 42 measures, with 
‘substance use’ and ‘psychological health’ among the commonest. Most measures were 
similar in content to each other and multidimensional. Almost all domains of problems 
identified in the outcome measures corresponded to concerns reported by patients. On the 
other hand, we found that several topics of relevance for patients were not covered by any of 
the measure included in our study. This suggests that existing outcome measurement does not 
always target aspects that affect patients’ lives, as reported directly by patients. Our study 
shows that outcome measurement needs to adopt a more flexible and comprehensive 
approach, by taking on board the problems experienced by patients in this population.  
Keywords: Outcome measurement; patient perspectives; thematic analysis.  
1.0 Introduction 
In substance use disorders, as in any other mental health intervention, outcome 
measurement plays a crucial role in understanding whether interventions are effective. Little 
is known about whether the traditional outcome measures used in this population cover the 
problems experienced by patients. This study aims to take a step in this direction, by 
reviewing outcome measures that are used to evaluate treatment for substance use disorders; 
as well as comparing the types of problems that such measures cover with the problems that 
patients in this population report having, when asked to talk freely about their clinical 
situation.  
1.1 Outcome Measurement In Large-Scale Studies 
To date, one of the largest outcome studies in this field was the National Treatment 
Outcome Research Study (NTORS; Gossop et al., 2003), conducted in the United Kingdom 
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in the early 2000s. This study investigated the outcomes of community and residential 
treatment in a national sample of 418 individuals using illicit drugs and alcohol. It revealed 
reductions in drug use and risk-taking behaviours, as well as improvements in psychological 
and physical health. Other large-scale outcome studies have reported similar findings (e.g., 
ATOS; Darke et al., 2007; DTORS; Jones et al., 2009). Gossop (2008) also referred to a 
“clinical fallacy”, which considers that numerous successful cases are overlooked in reports 
due to patients leaving the services voluntarily after self-perceived improvements. Although 
treatment drop-out can also represent treatment failure, these findings indicate that treatment 
for substance use disorders works, at least to a certain extent, and for a certain group of 
patients. 
However, for a relatively large proportion of people, treatment for substance use 
disorders is not as successful as desired. For instance, in NTORS, after a 5-year follow-up, 
there was still a 1% mortality rate and the levels of alcohol consumption remained unchanged 
among those that took part in the study. Moreover, an increase in frequency of alcohol use 
was observed in patients receiving residential treatment (Gossop, 2003). The latest report 
published by the National Drug Treatment Monitoring System of Public Health England 
(PHE, 2015) showed that approximately one third of patients (with opiate, non-opiate, non-
opiate/alcohol or alcohol problems only) left treatment prior to its completion or against the 
clinical judgement of practitioners (i.e., drop-out). It also revealed that one third of patients 
with opiate and/or non-opiate dependence problems remain unchanged after six months in 
treatment; and considering solely the alcohol problems, nearly half of all patients failed to 
improve.  
The reasons for these discouraging results are unclear, but unsuccessful treatment may 
negatively affect patients’ mental, physical and social status, and contribute to mortality 
excess in this group. On the other hand, individuals may have a variety of concerns or health 
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problems that is not captured by traditional methods of outcome measurement. Hence, there 
is a need to gain a better sense of which outcomes are relevant for this patient group and to 
reflect upon the value and relevance of the information which is being used for outcome 
measurement purposes.  
1.2 How Should We Measure The Outcomes Of Treatment? 
In 2011, Tiffany and colleagues stated that, to be effective, the measurement of 
treatment outcomes for substance use disorders should 1) focus on the consequences or 
strong, concurrent correlates of excessive drug use; 2) cover aspects that are common across 
abused substances and widespread among people dependent on those substances; and 3) have 
documented and strong psychometric properties that produce replicable evidence that the 
outcome can be altered following treatment. Despite providing a good framework, or 
strategy, for the evaluation of treatment for substance use disorders, Tiffany and colleagues 
(2011) proposal does not suggest which aspects should be covered by outcome measures in 
this field.  
There is a great diversity of outcome criteria proposed for substance use disorders 
treatment. However, the literature lacks consensus, with many international organisations 
(e.g., European Monitoring Centre for Drugs and Drug Addiction, EMCDDA) and authors 
suggesting different domains, or outcome measurement criteria (Table 1).  
Moreover, there is a gap between what is proposed in the literature and what is 
actually evaluated in research studies and/or practice. Most evaluation protocols focus on 
drug and/or alcohol use and related behaviours, e.g., injecting, criminal activities (Donavan et 
al., 2011; Tiffany et al., 2011), overlooking psychosocial variables that many authors believe 
to be highly relevant for patients’ recovery (Table 1). These data could be used as markers to 
adjust the intervention according to treatment response (Tiffany et al., 2011), as well as 
allowing for a better understanding of the mechanisms underlying recovery. 
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1.3 Does Outcome Measurement Reflect The Concerns Of Patients?  
The outcome measurement process in this patient group faces another major 
challenge: most measures are expert-driven, and not primarily sourced from patient 
perspectives. Failure to involve patients in the process of outcome measurement raises the 
possibility that measurement overlooks aspects of relevance for patients (Alves et al., 2016) 
and over-optimistic reporting of outcomes (Thurgood et al., 2014). Increasingly, studies are 
seeking the views of patients about outcome measurement criteria (e.g., Ruefli and Rogers, 
2004; Neale et al., 2016; see Table 1). For instance, Ruefli and Rogers (2004) revealed that 
patients in treatment stated the importance of domains covering: ‘making money’, ‘getting 
something good to eat’, ‘being housed’, ‘relating to family’, ‘getting needed 
programs/benefits/services’, ‘handling health problems’, ‘handling negative emotions’, 
‘handling legal problems’, ‘improving oneself’ and ‘handling drug-use problems’. In a 
similar study conducted in 2015, Neale and colleagues asked patients to define what “being 
recovered” meant for them. Patients reported that treatment recovery should include 
improvements in ‘substance use’, ‘material resources’, ‘outlook on life’, ‘self-care’ and 
‘relationships’. Another example is the recently developed ‘SURE’, a standardised outcome 
measure for treatment of substance use disorders (Neale et al., 2016). In this measure, items 
were generated in collaboration with former and current drug and alcohol service users 
(Neale et al., 2016). Similarly, our own research group has sought the views of patients with 
substance use disorders using individualised outcome measures, which enable patients to 
report their personal concerns at treatment entry (Alves et al., submitted). We found that 
patient priorities were ‘addictive behaviour’, ‘work-related problems’, ‘general relationships 
with family’, ‘money’ and ‘worries about another person’. Additionally, we found that most 
of the patient-reported topics were not captured by widely used standardised outcome 
measures of psychological well-being, such as CORE-OM or PHQ-9, or drug-related 
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outcome measures, as TOP (Alves et al., submitted). These findings suggest that patients may 
contribute new evidence to outcome measurement. Such evidence may provide insight into 
contradictory findings reported in the literature about the outcomes of treatment for substance 
use disorders.  
1.4 Study Rationale 
The principal aim of this study was to explore the thematic content of items used by 
outcome measurement tools in treatment for substance use disorders and to understand the 
extent to which these measures are perceived as relevant to this population. We hope that our 
findings will contribute to a broader understanding of the attributes of outcome measures and 
their ability to capture the personalised problems reported by patients.  
2.0 Methods 
This study was comprised of three analytical steps: to search for outcome measures 
and to identify the domains covered by those measures; to explore the extent to which the 
domains were duplicated in different measures, or were unique; and finally, to conduct a 
thematic comparison analysis comparing the ‘problem’ domains in standardised instruments 
with domains generated by patients, which had previously been derived from individualised 
measures in a previous study (Alves et al., submitted). 
2.1 Search Strategy, Selection Of Measures And Data Extraction  
A scoping review approach (Arksey and O’Malley, 2002) was used to extract 
information from the outcome measures. This approach was considered as the most 
appropriate because it allows for a rapid mapping of key concepts in a certain field, from the 
most relevant/main sources. With this methodology in mind, the key concepts used to chart 
our data were the general characteristics and domains covered by the outcome measures.  
For this study, we restricted our search to outcome measures used in Europe to match 
the setting in which the patient-driven domains used for comparison (see Data Analysis 
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section below) were developed. We believed this matching would decrease the existence of 
confounding factors (e.g., cultural differences) potentially affecting this comparison. After 
selecting the European setting, we started by hand searching for outcome measures at the 
website of EMCDDA, an EU Agency that aims to provide “factual, objective, reliable and 
comparable information concerning (…) drug addiction and their consequences” (see 
http://www.emcdda.europa.eu/about), including public policies, health responses and 
treatment. This Agency collects data about substance use disorder across 30 European 
countries. Stored data can be retrieved from the ‘Evaluation Instrument Bank’ 
(http://www.emcdda.europa.eu/eib). Twenty-six national agencies for drug and alcohol 
monitoring were also contacted by e-mail to ensure that all measures recommended for 
outcome measurement had been identified. No additional tools were identified by the six 
national agencies that responded to our request.  
Outcome measures were selected for review according to two inclusion criteria: 1) 
used to evaluate the outcome of treatment; and 2) used in adults as the target population. The 
measures were excluded if: 1) they did not target the patient (e.g., measures focusing on 
significant others); and 2) were not available in English. After selecting the outcome 
measures, a charting form was created for data recording. We extracted data describing 
general characteristics of the measures, by identifying their authors, year of publication, focus 
(drugs, alcohol, drug/alcohol, health, other), type of measure (standardised, individualised, 
hybrid), delivery format (self-report, interview, mixed) and number/type of items (Likert 
scales, nominal scales, number of days/times, other).  
2.2 Data Analysis  
2.2.1 Part 1: Identification of domains covered by outcome measures. We started by 
reading the Evaluation Instruments Bank’s “User information” sheet of each measure, which 
included a section about “Domains measure/life areas/problems assessed”. If unavailable, the 
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accompanying instructions or main references were consulted. A preliminary list of domains 
was then created, containing all domains included in each selected measure. In this list, 
domains were recorded verbatim as provided in the description of the measure. We removed 
duplicate domains and grouped those that referred to similar/equivalent topics, based on 
linguistic proximity (i.e., synonyms) until a complete list of domains was obtained. For 
instance, ‘illegal activities’ and ‘criminal involvement’ were both integrated in the domain 
‘crime’. In the case of ‘psychological health’, we opted for creating several sub-domains, due 
to the existence of instruments that either focussed on general or single aspects of 
psychological health (e.g., ‘self-esteem’). This procedure was performed by the first author 
and the results were discussed with a researcher, independent to the study, until consensus 
was reached.  
2.2.2 Part 2: Similarity between outcome measures in terms of domains covered. 
Next, we grouped the measures according to the similarity of the domains which they 
contained, to understand how convergent the tools were. To achieve this goal, we used the 
Metric-Frequency similarity index (Sales and Wakker, 2009; Sales et al., 2015) to obtain a 
similarity matrix, based on the ‘absence’ or ‘presence’ of each domain, in each tool. The 
similarity matrix was analysed with the Hierarchical Cluster Technique (centroid method) to 
obtain groups of measures that shared common features. We used IBM SPSS Statistics 22 
and the freeware online MF calculator (http://mfcalculator.celiasales.org/) to conduct this 
analysis.  
2.2.3 Part 3: Matching between outcome measure domains and the problems relevant 
for patients. The third part of our analysis comprised a thematic comparison between the 
domains extracted from the outcome measures and 54 previously defined domains of patient-
generated problems. This list of 54 patient-generated domains was identified in a study with 
93 patients entering treatment four clinical services for substance use disorders in a previous 
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study (Alves et al., submitted). This study was carried out in three outpatient and one 
inpatient service for treatment of substance use disorders in Portugal. It included 55 males 
and 38 females, with a mean age of 42.7 years old (SD = 11.3). Nearly half of the sample was 
married (48%) and the majority received education until years 5-9. More than half of the 
sample was unemployed (58%). In this study, patients were asked to identify their problems 
in two individualised outcome measures (one orally administered and one in a pen-and-paper 
format), as they were entering their first treatment session. Individualised measures are tools 
where individuals can report the concerns that led them to treatment, in an open-ended 
fashion and in their own words. The domains of patient-generated problems were derived 
from the categorisation of these problems, according to their underlying sub-theme.  
 The thematic comparison was made independently by two researchers with post-
graduate education in psychology and trained with the individualised outcome measures and 
the coding system used in this study. The researchers used a binary coding system to rate 
each outcome measure domain as “yes” (i.e., topics connected, clearly related or completely 
overlapped with patient-generated domains) and “no” (i.e., topics completely different from 
patient-generated domains). This procedure was followed by calculations of inter-rater 
reliability, based on Cohen’s kappa values. Certain outcome measures selected for review 
contained sections about socio-demographic/treatment history and treatment process (e.g., 
readiness for treatment). These sections were excluded from our thematic comparison, as we 
were interested in outcome criteria only. After completing the content matching, we 
calculated the number and percentage of patient-generated domains included in each of the 
outcome measures.  
Finally, for data reduction purposes, we re-analysed the data obtained from the 
thematic comparison of patient concerns to identify the presence of underlying constructs 
featured in the selected outcome tools. We only included those patient-generated domains 
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which were identified in at least 10% of the outcome measures. This cut-off was selected 
because less frequently featured domains were not present in a wide range of measures. This 
produced a cohort of 20 domains; the remaining 34 domains were discarded from this part of 
the analysis. To explore the structure of underlying constructs in selected domains, we used 
multiple correspondence analysis (MCA; Carvalho, 2008). MCA is a multivariate technique 
used to detect underlying dimensions among a group of nominal/categorical data. Factor 
analysis can also be used for a similar purpose; however, unlike factor analysis, MCA makes 
no assumptions of normality and can be used with categorical data (Carvalho, 2008; Philips, 
2009). Using MCA, dimensions are identified on the basis of their discriminatory and 
contribution values, in a range varying from zero to one.  
3.0 Results 
After removing the duplicates, 74 outcome measures were screened in this study, of 
which 42 fulfilled the selection criteria (see selection flowchart in Figure 1). 
3.1 Main Characteristics Of The Outcome Measures  
Among the 42 outcome measures, 25 (60%) focussed on drugs/alcohol, seven (17%) 
focused on drugs, six (14%) on alcohol, one (2%) on general health and three (7%) on other 
aspects (i.e., depression, self-esteem and quality of life). All but one measure were 
standardised, and only one differed by having an individualised scope, i.e., non-pre-set 
defined items. On delivery format, 21 (50%) were interview-based protocols, 19 (46%) were 
self-report measures, one (2%) was an observational scale and one (2%) followed a mixed-
methods approach. The mean number of items was 54 (SD = 57, range 1-223). Among these 
measures, 23 (55%) contained nominal items and 34 (81%) had scale-type items (see Table 
2). 
3.2 Domains Identified And Similarity Between Outcome Measures According To 
Domains Covered  
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From a preliminary group of 196 domains of problems identified across the measures, 
we obtained a final list of 31 domains by excluding all domains which had overlapping 
content. The full list of these domains is presented in Figure 2. 
The mean number of domains per measure was 4 (SD = 4, range 1-18); and 43% of 
measures (n = 18) covered only one domain. The most common domains were: ‘substance 
use’ (67%), ‘psychological health general (40%), ‘family and social relationships’ (38%), 
‘employment’ (38%), ‘crime’ (36%) and ‘physical health’ (26%).  
When exploring the similarity between the instruments in terms of domains covered, 
we found two main groups of measures: those that focussed only on substance use; and 
multidimensional measures focusing on substance use and other topics. A similarity tree 
representing these groups is shown in Figure 3. 
3.3 Comparison between outcome measure domains and patient-relevant problems  
The content matching between the 31 domains and the 54 domains of patient-
generated problems was performed with satisfactory inter-rater agreement values (Cohen’s 
kappa between raters ranged from 0.65 to 1.0). Overall, most patient-generated domains (n = 
34, 63%) were represented by a small proportion (10%) of outcome measures (see Table 3). 
Moreover, 26% of patient-generated domains (n = 14) did not feature in any of the outcome 
measures. Among the unmatched patient-generated domains were topics such as ‘personal 
development’, ‘understanding self’, ‘existence’, ‘outlook on life’, ‘moving on’, guilt’, 
‘bereavement’ and ‘dependence on other people’. On the other hand, nearly all 31 domains 
found in the outcome measures were matched, in terms of topics, to at least one patient-
generated sub-theme. The exceptions were the domains: ‘domestic life’, ‘self-care’, ‘daytime 
activities’, “technology and information’ and ‘acculturation’. We also found that the patient-
generated domains of problems frequently represented in outcome measures tend to focus on 
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four main areas: interpersonal relationships (dimension 1); communication problems 
(dimension 2); addiction (dimension 3); and social problems (dimension 4) (see Table 4). 
4.0 Discussion 
This study provides an overview of the measures recommended for outcome 
measurement in treatment for substance use disorders provided in Europe. Our goal was to 
identify the main characteristics of these measures; and, to explore the extent to which they 
covered individualised problems that bring patients to substance use disorders treatment. In 
the next paragraphs, we discuss the lessons derived from our findings.  
4.1 Lesson 1: Most outcome measures evaluate similar domains and are 
predominantly multidimensional  
In the 1960s professionals felt the need to employ methods to quantify substance use 
disorders that were being overlooked, which resulted in the proliferation of outcome tools 
(Dwyer and Fraser, 2015). Our study reveals that there is considerable duplication of the 
contents of outcome measures with consequent redundancy of measures in terms of topics 
covered. Hence, careful consideration of the domains worth measuring is required before 
selecting an outcome measure (Slade and Thornicroft, 2014).  
Our study revealed that outcome measures used in substance use disorders treatment 
can be clustered into two main groups. One group included unidimensional measures 
focussing on substance use. This was consistent with the study population and with the fact 
that most outcome studies focus solely on this topic. A second and larger group contained 
three types of measures covering: substance use and behaviours associated with this disorder 
(e.g., injection of drugs); substance use and psychological health; and domains not directly 
related to substance use (e.g., self-esteem). Psychological health was the second most 
commonly identified domain, featuring in nearly half the measures. Given the importance of 
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psychological health, these findings suggest that outcome measurement currently adopts a 
strategy to measure patients’ changes from a psychological point of view.  
These findings show that the “narrow” approach (Bühringer, 2012) that most outcome 
studies adopt is not due to the lack of multidimensional tools. Hence, it is the paradigm 
underlying outcome measurement that could adopt a broader approach by using more 
comprehensive measures. This is consistent with studies where patients in treatment for 
substance use disorders reported a need to talk about topics that go beyond their drug-related 
problems (Alves et al., 2016). Ultimately, using multidimensional tools could not only 
expand the scope of outcome measurement, by covering a greater variety of problems 
experienced by patients, but also shed light on situations that may trigger or motivate 
substance drug use. In other words, the more information one gathers about the individual 
circumstances that are related to patients’ addictive behaviour, the better prepared we will be 
to reflect on treatment priorities and relapse prevention.  
4.2 Lesson 2: The domains covered by outcome measures are relevant for patients  
Considering that outcome measures tend to be standardised and expert-driven, we 
were particularly interested in exploring the extent to which they reflected the personalised 
problems of patients in treatment for substance use disorders. We found that most domains 
(e.g., addiction, work-related problems, relationship difficulties, money worries) covered by 
outcome measures were equivalent to problem domains reported by patients with substance 
use disorders. Relevance to patients was demonstrated by findings reported in a previous 
study in which patients had reported that outcome measurement targeting substance use 
helped them to think about the negative consequences of their addictive behaviour (Alves et 
al., 2016). Moreover, the patient-generated domains which also featured in the outcome tools 
tended to focus on interpersonal and/or social relationships, concerns which are reported by 
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20% of patients in treatment for substance use disorders, reinforcing the evidence that 
outcome measures was addressing concepts of interest to patients (Alves et al., submitted).  
4.3 Lesson 3: The outcome measures available are overlooking areas of concern to 
this population 
 To this point, we have showed that the existing measures tend to cover topics of 
relevance for patients, which was a positive finding. However, we also found that despite 
including relevant topics, they tend to miss areas of problems that patients deem as important 
and that should have been measured. More specifically, our study revealed that only 10% of 
outcome measures contained half or more of the patient-generated domains identified by our 
study. The remaining 90% of measures contained under half these domains. Some patient-
generated domains overlooked by outcome measures reflected specific concerns likely to be 
experienced by a small minority (e.g., ‘bereavement’). However, more universally 
experienced psychological factors or distressing events such as ‘guilt’, ‘dependence of other 
people’ or ‘housing problems’ were rarely included in outcome measures. None of the 
measures included worries about the self (e.g., ‘personal development’, ‘existence’, ‘outlook 
on life’, ‘having time’) even though these were frequently reported in individualised 
measures (Alves et al., submitted). Some of these patient-generated topics, namely, ‘self-
care’ and ‘outlook on life’, have recently been incorporated into a new standardised measure, 
‘SURE’, a patient-reported outcome measure for use in substance use (Neale et al., 2016).  
Our study suggests that patients seeking treatment for substance use disorders are 
likely to have a greater diversity of concerns than has previously been acknowledged by 
experts in the process of designing outcome measures. However, one cannot expect a single 
outcome measure to be able to address all concerns that patients have about their lives. For 
this reason, we suggest the use of a more open-ended approach to outcome measurement 
which elicits a broader range of information from patients. This open-ended approach would 
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allow patients to talk about whichever topic was troubling them, without limiting the scope of 
their clinical situation. This could be achieved using the so-called individualised outcome 
measures (Sales and Alves, 2016), measures that do not contain items created a priori by 
experts, but instead invite patients to write or talk about the main concerns that led them to 
seek treatment. In addition to informing clinicians about the whole range of patients’ 
problems, open-ended individualised measures could also identify problems that may be of 
greater concern for the patient than substance use itself, at least in the short-term, which may 
result in referral to other specialist services. 
4.4 Implications for outcome measurement in treatment for substance use disorders  
We believe that our study has provided an insight into the limitations of current 
outcome measures and how we can improve outcome measurement by producing more 
informed (and less contradictory) findings about treatment outcomes. Based on our study of 
measures used in Europe, we recommend that health and policy bodies identify a core-set of 
outcome criteria for use in treatment evaluation, thus facilitating the selection of outcome 
tools. However, it is important that both researchers/professionals and patients are engaged 
with this task. Although standardised outcome measures tend to cover relevant domains, they 
also overlook relevant information about individual distress. As Slade and Thornicroft (2014) 
put it, “any attempt to squeeze personal identity into predefined boxes can be justifiably 
criticised for its loss of meaning” (p. 120). This problem could be overcome using a more 
patient-centred approach to outcome measurement, by using individualised measures (see 
Sales and Alves, 2016, for a review about these tools), which allow patients to express their 
personal problems. We advocate that individualised measures are used in combination with 
existing standardised measures, which provide population reference data. If the use of 
individualised measures is not feasible, a standardised patient-reported outcome measure 
designed with a high level of patient input may be a suitable alternative. Although “imperfect 
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measures are better than no measures at all” (Scheyett et al., 2013), the addition of items 
deemed important by patients has the potential to improve outcome measurement.  
4.5 Limitations 
This study is not without limitations. First, we accept that some outcome measures 
may have been omitted from our study if they were not included in the EMCDDA database. 
However, our goal was to confine our search to measures recommended by international 
agencies. Restriction of our search to Europe may have restricted our findings although 
measures need to be culturally applicable (Mann (2012). A further limitation is that our 
review did not differentiate between measures used for subgroups of patients. For instance, 
we did not included measures targeting adolescents since the patient-generated domains used 
for comparison purposes were derived from an adult population. We believe that this present 
study adds up to an increasing body of literature demonstrating the importance of 
multidimensional outcome measurement in substance use disorders and the inclusion of 
patient perspectives. Such an approach would acknowledge the multiplicity of problems 
associated with substance use disorders, as well as taking into account the concept that 
recovery is an individual journey.  
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Figure Legends 
Figure 1: Flowchart showing the selection of outcome measures for review 
Figure 2: List of domains (N = 31) ordered by frequency of outcome measures featuring each 
domain 
Figure 3: A similarity tree grouping the 42 outcome measures, based on their proximity in 
terms of domains covered 
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Table 1: Examples of domains (i.e., outcome criteria) to use during outcome measurement of 
treatment for substance use disorders, as suggested by experts  
Type of 
publication 
Authors/year  Source  Criteria suggested for outcome measurement 
International 
guidelines 
EMCDDA, 
2007 
EU Agency  Addictive behaviour/consumption of substances, 
retention/time in treatment, status at discharge 
(planned / drop-out), risk-taking behaviours for drug-
related infection, somatic and psychiatric health, 
social reintegration (housing, employment, social 
network, life style, delinquency), and quality of life 
Scientific 
literature 
Tiffany et al., 
2011 
Addiction research 
experts  
Self-efficacy, psychosocial functioning, 
network/social support, craving and quality of life 
Scientific 
literature 
Donavan et 
al., 2011 
Addiction research 
experts  
Behavioural functioning and quality of life  
 
Scientific 
literature 
Neale et al., 
2015 
Addiction research 
experts  
Substance use, treatment/support, psychological 
health, physical health, use of time, 
education/training/employment, income, housing, 
relationships, social functioning, offending/anti-
social behaviour, well-being, identity/self-awareness, 
goals/aspirations and spirituality 
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Table 2: Review of the outcome measures used in treatment for substance use disorders (N = 
42), including the identification of domains (N = 31).  
 Author/Yea
r 
Focus Type of 
measure 
Delivery 
format  
No. 
items 
Type of 
items 
Domains 
Addiction 
Severity 
Index  
McLellan et 
al., 1979 
Drugs/alcoho
l 
Standardise
d 
Intervie
w 
161 Nominal
, scale  
Crime, 
employment, 
family/relationshi
ps, general health, 
money, 
psychological 
health, substance 
use  
 
Addiction 
Severity 
Index  
Crime  
Öberg et 
al., 1998 
Drugs/alcoho
l 
Standardise
d 
Intervie
w 
39 Nominal
, scale  
Crime 
 
Addiction 
Severity 
Index 
Gambling  
 
 
Öberg et 
al., 1999 
 
Drugs/alcoho
l 
 
Standardise
d 
 
Intervie
w 
 
15 
 
Scale 
 
Gambling 
Alcohol 
Dependence 
Data 
Questionnair
e  
 
Raistrick, 
1983 
Alcohol Standardise
d 
Self-
report 
15 Scale  Substance use 
Alcohol 
Dependence 
Scale  
 
Skinner, 
1982 
Alcohol Standardise
d 
Self-
report 
25 Nominal  Substance use 
Depression 
Scale  
Radloff, 
1977 
Other Standardise
d 
Self-
report 
20 Scale  Depression/anxiet
y/stress, 
family/social 
relationships, 
physical health 
 
Christo 
Inventory for 
Substance 
Misuse 
Services 
Christo, 
Spurrell and 
Alcorn, 
2000 
Drugs/alcoho
l 
Standardise
d 
Intervie
w 
10 Nominal Crime, 
employment, 
general health, 
psychological 
health, 
psychosocial 
functioning, risk 
behaviours, 
substance use 
 
Christo 
Inventory of 
Drugs  
 
Christo, 
n.d. 
Drugs/alcoho
l 
Standardise
d 
Intervie
w 
8 Nominal
, scale 
Substance use 
Clinical 
Opiate 
Withdrawal 
Scale  
Wesson and 
Ling, 2003 
Drugs Standardise
d 
Intervie
w 
11 Nominal Substance use 
31 
 
 
Drug Abuse 
Screening 
Test  
Gavin, 
Ross, and 
Skinner, 
1989 
Drugs/alcoho
l 
Standardise
d 
Self-
report 
20 Nominal Crime, 
employment, 
family/social 
relationships, 
psychological 
health 
 
Drug 
Avoidance 
Self-Efficacy 
Scale  
 
Martin, 
Wilkinson, 
and Poulos, 
1995 
Drugs/alcoho
l 
Standardise
d 
Self-
report 
16 Scale Self-efficacy 
European 
Addiction 
Severity 
Index 
(EuropASI) 
Blacken et 
al., 1994 
Drugs/alcoho
l 
Standardise
d 
Intervie
w 
189 Nominal
, scale 
Crime, 
employment, 
family/social 
relationships, 
money, 
psychological 
health, substance 
use 
 
Evaluate 
Your Alcohol 
Consumption 
 
Sobell and 
Sobell, 
1992 
Alcohol Standardise
d 
Self-
report  
1 Scale Substance use 
Evaluate 
Your Drug 
Consumption 
  
Sobell et 
al., 1996 
Drugs Standardise
d 
Self-
report 
1 Scale Substance use 
The Health 
Questionnair
e  
 
Brodman et 
al., 1949 
Health Standardise
d 
Self-
report 
144 Nominal  Physical health 
Leeds 
Dependence 
Questionnair
e 
  
Raistrick et 
al., 1994 
Drugs/alcoho
l 
Standardise
d 
Self-
report 
10 Scale  Substance use  
Lifetime 
Drinking 
History  
 
Skinner, 
1982 
Alcohol Standardise
d 
Intervie
w 
8 Nominal
, scale 
Substance use 
Maudsley 
Addiction 
Profile  
Marsden et 
al., 1998 
Drugs/alcoho
l 
Standardise
d 
Intervie
w 
61 Nominal
, scale 
Crime, 
employment, 
family/social 
relationships, 
physical health, 
psychological 
health, 
psychosocial 
functioning, risk 
behaviours, 
substance use 
 
Measurement
s in the 
Addictions 
for Triage 
Schippers, 
Broekman, 
Buchholz 
and Rutten, 
2009 
Drugs/alcoho
l 
Standardise
d 
Intervie
w 
114 Nominal
, scale 
Community/civic 
life, 
depression/anxiety
/stress, domestic 
life, employment, 
32 
 
and 
Evaluation  
family/social 
relationships, 
money, 
personality, 
physical health, 
school, self-care, 
social life, 
substance use 
 
Monitoring 
Area and 
Phase System 
- Intake  
Öberg et 
al., 1997 
Drugs/alcoho
l 
Individualis
ed 
Intervie
w 
7 Nominal Crime, 
employment, 
family/social 
relationships, 
physical health, 
psychological 
health, substance 
use 
 
Monitoring 
Area and 
Phase System 
- Out  
Öberg et 
al., 1997 
Drugs/alcoho
l 
Standardise
d 
Intervie
w 
223 Nominal
, scale  
Crime, 
employment, 
family/social 
relationships, 
physical health, 
psychological 
health, substance 
use 
 
Monitoring 
Area and 
Phase System 
- Up  
Öberg et 
al., 1997 
Drugs/alcoho
l 
Standardise
d 
Intervie
w 
102 Nominal
, scale 
Crime, 
employment, 
family/social 
relationships, 
physical health, 
psychological 
health, substance 
use  
 
Objective 
Opiate 
Withdrawal 
Scale  
 
Handelsma
n et al., 
1987 
Drugs Standardise
d 
Observa
-tional  
13 Nominal  Substance use  
Opiate 
Treatment 
Index 
Darke, 
Ward, Hall, 
Heather and 
Wodak, 
1991 
 
 
Drugs Standardise
d 
Intervie
w 
104 Nominal
, scale  
Crime, physical 
health, use  
 
Personal 
Experience 
Screening 
Questionnair
e  
 
Winters, 
1992 
Drugs/alcoho
l 
Standardise
d 
Self-
report 
40 Scale  Psychosocial 
functioning, 
substance use 
Rosenberg 
Self-Esteem 
Scale  
 
Rosenberg, 
1965 
Other  Standardise
d 
Self-
report  
10 Scale  Self-esteem 
33 
 
Severity of 
Dependence 
Scale  
 
Gossop et 
al., 1995 
Drugs Standardise
d 
Self-
report  
5 Scale  Substance use 
Goals of 
Treatment 
Questionnair
e  
Joosten et 
al., 2009 
Drugs/alcoho
l 
Standardise
d 
Mixed  24 Nominal Child care, 
community/civic 
life, crime, 
daytime activities, 
domestic life, 
family/social 
relationships, food 
and nutrition, 
gambling, housing 
status, money, 
physical health, 
psychological 
health, school, 
self-control, 
sexual 
functioning, social 
life, substance use, 
technology and 
information 
 
Situational 
Confidence 
Questionnair
e  
Annis and 
Martin, 
1985 
Alcohol Standardise
d 
Self-
report  
39 Scale  Emotions, 
employment, 
physical health, 
self-control, social 
life 
 
Situational 
Confidence 
Questionnair
e - Heroin  
Barber, 
Cooper and 
Heather, 
1991 
Drugs Standardise
d 
Self-
report  
22 Scale  Emotions, 
family/social 
relationships, 
physical health, 
self-control, social 
life  
 
Subjective 
Opioid 
Withdrawal 
Scale  
 
Handelsma
n et al., 
1987 
Drugs Standardise
d 
Self-
report  
16 Scale  Substance use 
        
The Texas 
Christian 
University - 
Initial 
Assessment - 
Methadone 
Outpatient 
 
 
Texas 
Christian 
University, 
1995 
Drugs/alcoho
l 
Standardise
d 
Intervie
w 
58 Nominal
, scale  
Employment, 
psychosocial 
functioning, 
substance use 
        
The Texas 
Christian 
University 
Intake - 
Methadone 
Outpatient 
Texas 
Christian 
University, 
1997 
Drugs/alcoho
l 
Standardise
d 
Intervie
w 
119 Nominal
, scale  
Acculturation, 
crime, 
employment, 
family/social 
relationships, 
gambling, general 
health, money, 
psychological 
34 
 
health, 
psychosocial 
functioning, risk 
behaviours, 
substance use 
 
Texas 
Christian 
University 
Follow - Up 
Interview - 
Methadone 
Outpatient 
Texas 
Christian 
University, 
1997 
Drugs/alcoho
l 
Standardise
d 
Intervie
w 
84 Nominal
, scale  
Crime, 
employment, 
family/social 
relationships, 
gambling, general 
health, leisure 
activities, money, 
psychological 
health, risk 
behaviours, 
substance use 
        
The Texas 
Christian 
University - 
Initial 
Assessment- 
Correctional 
Residential 
 
Texas 
Christian 
University, 
1998 
Drugs/alcoho
l  
Standardise
d 
Intervie
w 
114 Nominal
, scale  
Employment, 
psychological 
health, 
psychosocial 
functioning, 
substance use  
The Texas 
Christian 
University - 
Intake - 
Correctional 
Residential 
 
Texas 
Christian 
University, 
1998 
Drugs/alcoho
l 
Standardise
d 
Self-
report 
95 Scale  Psychological 
health, 
psychosocial 
functioning 
The Texas 
Christian 
University 
HIV/AIDS 
Risk 
Assessment 
 
Texas 
Christian 
University, 
1997 
Drugs/alcoho
l 
Standardise
d 
Intervie
w 
19 Scale  Risk behaviours 
The Texas 
Christian 
University 
Self Rating at 
Intake - 
Methadone 
Outpatient 
 
Texas 
Christian 
University, 
1996 
Drugs/alcoho
l 
Standardise
d 
Intervie
w 
95 Scale  Psychological 
health, 
psychosocial 
functioning 
The Texas 
Christian 
University- 
Evaluation of 
self and 
treatment 
Texas 
Christian 
University, 
1996 
Drugs/alcoho
l 
Standardise
d 
Self-
report 
126 Scale  Crime, 
employment, 
family/social 
relationships, 
housing status, 
risk behaviours, 
substance use  
 
The WHO 
Quality of 
Life-Bref 
instrument 
Skevington,
 Lotfy, 
and O'Conn
el, 2004 
Other  Standardise
d 
Self-
report  
26 Scale  Family/social 
relationships, 
psychological 
health, social life  
35 
 
 
Timeline 
Followback 
Method 
Robinson, 
Sobell, 
SobelL, and 
Leo, 2014 
Alcohol Standardise
d 
Self-
report  
1 Scale  Substance use  
 
 
 
 
 
Table 3: Number and percentage of outcome measures featuring the 54 patient-generated sub-
theme of problems  
Patient-generated sub-themes  No. instruments with sub-theme 
present (%)  
Addiction  28 (67) 
Work-related problems 15 (36) 
Relationships difficulties: family-general 13 (31) 
Money worries 7 (17) 
Relationship difficulties: family - worry about another 15 (36) 
Justice-related problems 15 (36) 
Worries about health 10 (24) 
Self image/self worth 1 (2) * 
Coping:daily living 7 (17) 
Loneliness/being alone 2 (5) * 
Global 0 (0) * 
Depression/Anxiety 15 (36) 
Motivation 4 (9) * 
Emotions – unspecified 2 (5) * 
Relationship difficulties: family - breaking up 15 (36) 
Relationships-general 14 (33) 
Relationship difficulties: family – conflict 1 (2) * 
Socialising 8 (19) 
Agression/irritability 1 (2) * 
Housing worries 2 (5) * 
Relationship difficulties partner - breaking up 15 (38) 
Communication 5 (12) 
Relationship diffculties: family – caring 1 (2) * 
Being happy 2 (5) * 
Dependence on other people 0 (0) * 
Guilt 0 (0) * 
Suicidal thoughts 9 (19) 
Understanding self/events 0 (0) * 
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Existence/existential 0 (0) * 
Future 0 (0) * 
Relationship difficulties: partner – conflict 2 (5) * 
Concentration 9 (21) 
Coping: general 0 (0) * 
Fears/panics 3 (7) * 
Moving on 0 (0) * 
OCD 2 (5) * 
Personal development 0 (0) * 
Sleep problems 2 (5) * 
Studies-related problems 2 (5) * 
Victim of abuse/sexual violence 1 (2) * 
Achievement 1 (2) * 
Attemped Suicide 4 (9) * 
Bereavement 0 (0) * 
Coping: feelings 0 (0) * 
Eating problems 1 (2) * 
Going out/travelling 6 (14) 
Having positive Outlook 0 (0) * 
Having time 0 (0) * 
Outlook on life 0 (0) * 
Relationship difficulties: partner – development 15 (36) 
Relationship difficulties: partner – general 6 (14) 
Relationship difficulties: partner - worry about another 15 (36) 
Self-acceptance 1 (2) * 
Sexual problems 1 (2) * 
Note: The values highlighted with a * represent sub-themes covered by <10% of 
outcome measures.  
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Table 4  
Dimensions (of patient-generated sub-themes) covered by the outcome measures, based on the multiple correspondence analysis  
 Dimensions        
 1  2  3  4  
Variables 
(patient-generated 
sub-themes) 
Discrimination Contribution 
(%) 
Discrimination Contribution 
(%) 
Discrimination Contribution 
(%) 
Discrimination Contribution 
(%) 
Addiction 0.003 0.0 0.021 0.7 0.437 22.0 0.155 11.1 
Communication 0.000 0.0 0.589 18.7 0.252 12.7 0.079 5.6 
Concentration 0.214 2.5 0.359 11.4 0.252 12.7 0.024 1.7 
Coping: daily 
living 
0.002 0.0 0.397 12.6 0.180 9.1 0.001 0.1 
Depression/Anxiety 0.459 5.4 0.239 7.6 0.085 4.3 0.000 0.0 
Going 
out/travelling 
0.012 0.1 0.607 19.3 0.233 11.7 0.023 1.6 
Justice-related 
problems 
0.498 5.9 0.002 0.1 0.001 0.1 0.236 16.8 
Money worries 0.397 4.7 0.053 1.7 0.002 0.1 0.103 7.4 
Relationship 
difficulties: family 
- breaking up 
0.867 10.3 0.074 2.3 0.012 0.6 0.027 1.9 
Relationships 
difficulties: family-
general 
0.531 6.3 0.008 0.3 0.003 0.2 0.032 2.3 
Relationship 
difficulties: family 
- worry about 
another 
0.867 10.3 0.074 2.3 0.012 0.6 0.027 1.9 
Relationship 
difficulties partner - 
breaking up 
0.867 10.3 0.074 2.3 0.012 0.6 0.027 1.9 
Relationship 
difficulties: partner 
– development 
0.867 10.3 0.074 2.3 0.012 0.6 0.027 1.9 
Relationship 
difficulties: partner 
– general 
0.268 3.2 0.001 0.0 0.029 1.5 0.028 2.0 
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Relationship 
difficulties: partner 
- worry about 
another 
0.867 10.3 0.074 2.3 0.012 0.6 0.027 1.9 
Relationships-
general 
0.579 6.9 0.011 0.3 0.021 1.1 0.003 0.2 
Socialising 0.108 1.3 0.086 2.7 0.083 4.2 0.373 26.6 
Suicidal thoughts 0.187 2.2 0.400 12.7 0.188 9.5 0.095 6.8 
Work-related 
problems 
0.466 5.5 0.009 0.3 0.132 6.7 0.035 2.5 
Worries about 
health 
0.366 4.3 0.000 0.0 0.024 1.2 0.077 5.5 
Active total  8.424 100.0 3.149 100.0 1.983 100.0 1.401 100.0 
Inertia / Variance  0.421  0.158  0.099  0.070  
Note: The values, which vary between 0 and 1, indicate how much each variable contributes to/is present in each dimension (i.e., higher 
values indicate a greater contribution).  
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